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Abstract
Bacterial vaginosis (BV) is one of the great enigmas in women’s health, a common condition of unknown aetiology,
which is associated with significant morbidity and unacceptably high recurrence rates. While it remains unclear whether
BV recurrence is predominantly due to failure of current antibiotic regimens to eradicate BV-associated bacteria (BVAB)
and biofilm, a failure of some women to re-establish a resilient Lactobacillus-dominant vaginal microbiota, reinfection
from sexual partners, or a combination of these factors, it is inherently challenging to make significant inroads towards
this goal. In this review, we will outline why BV is such a clinical and epidemiologic conundrum, and focus on several
key approaches that we believe merit discussion and clinical research, including strategies to: i) prevent reinfection
(partner treatment trials), ii) boost favourable vaginal Lactobacillus species and promote a Lactobacillus-dominant vaginal
microbiome (hormonal contraceptive and probiotic trials) and iii) disrupt vaginal BV-associated biofilm.
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Introduction
Bacterial vaginosis (BV) is one of the great enigmas
in women’s health, a common condition of unknown
aetiology, which is associated with significant morbid-
ity and unacceptably high recurrence rates. In this re-
view, we will outline why BV is such a clinical and
epidemiologic conundrum, and propose key research
priorities that focus on the common goal, the elusive
sustained cure.
Background
BV is the most common vaginal infection in women of
reproductive age. Prevalence estimates range from 12 %
in Australian women [1], to 29 % in North-American
women [2, 3], and greater than 50 % in women in
East/Southern Africa [4]. BV has been associated with
serious and costly reproductive and obstetric sequelae,
increasing women’s risk of pre-term delivery, low birth
weight, miscarriage and pelvic inflammatory disease [5].
These sequelae have considerable implications for
healthcare expenditure, with the population attributable
risk of BV for pre-term delivery in the US estimated
over a decade ago to be 30 %, at a cost of USD 1 bil-
lion per annum [5].
Longitudinal studies have demonstrated that BV is
associated with an approximate 2-fold increased risk of
acquiring sexually transmitted infections including
chlamydia, gonorrhoea, herpes simplex type 2 and HIV
infection [6–11], and increases the risk of co-infected
women transmitting HIV to their male partners [12].
Although significant proportions of women with BV
appear to be asymptomatic, over 50 % experience an
unpleasant vaginal malodour and discharge, with quali-
tative studies showing BV is associated with moderate-
severe impact on self-esteem, sexual relationships and
quality of life in women who have sex with men (WSM)
and women who have sex with women (WSW) [13].
While the aetiology and pathogenesis of BV is not com-
pletely understood, BV is characterised by depletion of key
Lactobacillus spp., high bacterial species diversity and in-
creased loads of facultative anaerobes such as Gardnerella
vaginalis, Atopobium vaginae and other fastidious BV-
associated bacteria (BVAB) including Megasphaera,
Sneathia and Clostridiales spp. compared to healthy con-
trols [14–16]. Most vaginal Lactobacillus spp. provide
broad-spectrum protection against pathogens through
production of potent antimicrobial molecules, bacteriocins
and lactic acid [17–19], with the latter acting as a broad-
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spectrum bactericide and virucide, and maintaining vagi-
nal pH between 3.5 and 4 [20, 21]. Lactic acid appears to
possess antimicrobial activity beyond acidity alone, by dis-
rupting the integrity of bacterial cell membranes and
stimulating innate immunity in the presence of bacterial
lipopolysaccharide [20–22]. Recent work has also demon-
strated that lactobacilli can interfere with the ability of
pathogens such Trichomonas vaginalis to adhere to host
cells [23]. Overall there is a significant body of evidence
indicating most Lactobacillus-dominant vaginal micro-
biomes, with the exception of L. iners [24–29], are optimal
for maintaining vaginal and reproductive health.
Recent work has identified a vaginal wall biofilm in
women with BV, dominated by G.vaginalis and A.vaginae,
that is absent in healthy controls [30, 31]. While it is
thought this biofilm may contribute to the low success
rate of current antibiotic therapies, the role of the biofilm
in BV pathogenesis is not clear as in vivo vaginal epithelial
cells are shed rapidly throughout the menstrual cycle [32].
BV research is further impeded by the fact that primate
and other animal models are not optimal for the study of
the cervico-vaginal microbiota because the vaginal pH is
higher (>5) and the resident microbiota differ from that of
humans [33–37]. There are, for example, high proportions
of streptococci in mice [35] and Corynebacterium in the
guinea pig [34]. Humans also have significantly lower bac-
terial richness and diversity estimates compared to non-
human primates, and the relative abundances of lactoba-
cilli are significantly lower in non-human primates [33].
While short term BV cure rates following first line
recommended therapies (5–7 days of metronidazole or
clindamycin) approach 80 % [38], failure rates in excess
of 50 % occur within 6–12 months [39, 40]. Higher
baseline loads of several BVAB have been associated
with increased risk of recurrence [41], and some data
suggest BV-associated biofilm rapidly re-accumulates
following antibiotics [31]. However, strategies such as
suppressive antibiotic regimens that attempt to eradi-
cate persistence of BVAB, have not achieved sustained
high long term cure [42, 43].
While it remains unclear whether BV recurrence is
predominantly due to failure of current antibiotic regi-
mens to eradicate BVAB and biofilm, a failure of some
women to re-establish a resilient Lactobacillus-dominant
vaginal microbiota, reinfection from sexual partners, or
a combination of these factors, it is inherently challen-
ging to make significant inroads towards this goal, Fig. 1.
We will focus this review on several key approaches that
we believe merit discussion and clinical research, including
strategies to: i) prevent reinfection (partner treatment tri-
als), ii) boost favourable vaginal Lactobacillus species and
promote a Lactobacillus-dominant vaginal microbiome
(hormonal contraceptive and probiotic trials) and iii) dis-
rupt vaginal BV-associated biofilm.
Strategies to address potential reinfection (partner
treatment trials)
BV has been strongly associated with sexual activity in
epidemiological studies. Women with BV have an earlier
median age of sexual debut than women without BV [44],
and BV has been associated with increased numbers of re-
cent and lifetime sexual partners and inconsistent condom
Fig. 1 BV recurrence and potential therapeutic strategies
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use by meta-analysis [45]. A study of young female univer-
sity students found BV to be absent in women with no
history of sexual activity, to be uncommon in women who
had engaged only in non-coital sexual activities and to be
significantly associated with penile-vaginal sex [46]. Prior
studies identifying BV in “virgins” had limited questioning
to history of penile-vaginal sex [47, 48]. The concept that
BV may be sexually transmitted has been controversial for
many years due to difficulties encountered in determining
its aetiology, absence of corresponding disease in males,
and failure of male partner treatment trials to reduce re-
currence [49, 50]. A recent systematic review by Mehta
concluded that insufficient power, use of non-standard
treatment regimens, no measures of adherence, and poor
retention, rendered the findings of past partner treatment
trials inconclusive by current standards, and recom-
mended larger trials using recommended therapies be
conducted [50]. Further support for sexual transmission of
BV includes published data which indicates that the poor
long-term performance of recommended therapies may at
least partly be attributed to post-treatment sexual behav-
iours. Women exposed to an ongoing partner pre- and
post-treatment were at a 2–3 fold increased risk of BV re-
currence after adjusting for sexual frequency, condom use
and hormonal contraception in two studies [40, 51], and
several, but not all studies, found inconsistent condom use
and unprotected penile-vaginal sex to be associated with
recurrence [51–53]. Male carriage of G.vaginalis, an organ-
ism implicated in the development of BV [54], is com-
monly reported [55–57]. Pyrosequencing of the microbiota
of the coronal sulcus and distal-urethra in young males has
also showed these sites to be colonised by BVAB, and the
composition of the sulcus microbiota to be influenced by
circumcision and sexual activity [58]. Male circumcision
was not only associated prospectively with a significant
reduction in penile anaerobes, including BV-associated
genera [59], but a secondary analysis within a male cir-
cumcision trial showed wives of circumcised males had a
reduced risk of BV (adjPRR = 0.60; 95 % CI = 0.38-0.94)
compared to wives of controls [60]. While there are few
studies examining BV-associated biofilm in men, biofilm
has been detected in male urine and semen, and more
commonly found in the male partners of females with BV
than healthy controls [61]. Overall this body of evidence
provides increasing support for the hypothesis that BV is
sexually transmitted between men and women.
International BV research has had a strong focus on
women who predominantly have sex with men. How-
ever, WSW also experience BV and are in need of rele-
vant clinical and epidemiological research. A number of
studies have confirmed BV to be prevalent in WSW with
estimates ranging from 25 to 52 % [62–66]. Female
same-sex partnerships provide an important model to
understand the pathogenesis and transmissibility of BV,
as unlike in male–female partnerships, BV can be diag-
nosed in both partners. BV has been strongly associated
with sexual risk factors in WSW including: increased
number of female partners, a female partner with BV
and receptive oral sex [63, 65–68]. Female couples in
monogamous relationships have high concordance of
Nugent category [62, 63, 65, 66, 68], and share
Lactobacillus strain types [69]. In a recent community-
based cohort study of 298 WSW, incident BV was signifi-
cantly associated with exposure to a new female sexual
partner and a female partner with BV symptoms [68]. In
contrast, co-enrolled couples who were BV-negative at en-
rolment had a very low risk of incident BV over two years,
and their vaginal microbiota remained aligned, stable and
within the “normal” Nugent category. This study provides
compelling evidence for dynamic exchange of vaginal bac-
terial species between female partners, and extends our
understanding of the influence of sexual behaviours and
relationships on the vaginal microbiota and risk of BV.
Collectively, published clinical and epidemiological
data suggests sexual transmission of BV is at least likely
to be contributing to the development of BV and to
post-treatment recurrence. These data provide broad
support for the need to repeat and fund sufficiently pow-
ered male and female partner treatment trials to deter-
mine if this strategy reduces BV recurrence and
associated sequelae. There is currently one registered
male partner treatment trial enrolling couples in North
America in which men are randomized to oral metro-
nidazole versus oral placebo and these data are eagerly
awaited (ClinicalTrials.gov Identifier: NCT02209519).
Trials involving the use of topical in addition to oral
agents are planned, and may be necessary to eradicate
cutaneous carriage of BVAB from the penile skin. Fe-
male partner treatment trials, while clearly needed, are
logistically more challenging as randomization of symp-
tomatic female partners to treatment or placebo may
not be acceptable or ethical; the design of such studies
will clearly need careful thought and innovation.
Strategies to boost favourable Lactobacillus spp.: vaginal
probiotics and hormonal contraceptives
Surveys of the vaginal microbiota have found there are fun-
damental differences in the microbial diversity of vaginal
communities present in reproductive age women [70–76].
In one U.S. study of 394 women, Ravel et al. characterized
the vaginal microbiota using 16S rRNA gene analysis amp-
lified from whole genomic DNA isolated from vaginal
swabs [70], Fig. 2. Five vaginal microbiota groupings,
termed community state types (CSTs), were identified.
Four CSTs were dominated by one of four Lactobacillus
species, while the fifth was depleted of Lactobacillus. The
latter CST contained high proportions of anaerobic bac-
teria, resembling BV. The frequencies of each CST varied
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by ethnicity, and African American and Hispanic women
were more likely to be Lactobacillus-depleted. Longitudinal
studies have also demonstrated that some women experi-
ence frequent and rapid fluctuations in the composition of
the vaginal microbiota, while in others, the microbiota are
remarkably stable [77–79], Fig. 3. These surveys are par-
ticularly relevant to the development of probiotics, which
aim to reseed dysbiotic microbiomes.
Probiotics that have been evaluated in studies have
contained a range of Lactobacillus spp. (L. acidophilus,
L. gasseri. L. fermentum. L. rhamnosus and L. crispatus),
not all of which are endogenous to the vagina. In 2009, a
Cochrane review found no conclusive evidence to rec-
ommend for or against probiotic use for the treatment
of BV [80]. However, a recent body of research has begun
to rigorously evaluate the efficacy of intravaginal and oral
probiotic formulations to treat BV and to restore a
Lactobacillus-dominant microbiota [80–83]. In a study of
90 women without BV who used the intravaginal delivery
of L. crispatus CTV-05, Antonio et al. reported good
CTV-05 colonization rates (59 %) at 28 days [83]. Subse-
quently, Ngugi et al. reported on the use of CTV-05 in 24
women with BV [84] and reported 44 % of BV cases were
colonized with CTV-05 at 28 days, and cases not colo-
nized had higher median concentrations of BV-associated
bacteria. Those who were colonized had significant re-
ductions in Atopobium vaginae, a bacterium associ-
ated with BV. Importantly, vaginal intercourse was
found to significantly impair CTV-05 colonization in
both studies, and endogenous L. crispatus also re-
duced the CTV-05 colonization rate [83, 84]. Clinical
trials to assess the efficacy of CTV-05 for BV are in
progress. A study of another intravaginal probiotic
(containing L. brevis, L. salivarius subsp. salicinius,
and L. plantarum) found 61 % did not have BV by
Amsel and Nugents criteria at 2 weeks compared to
19 % in the placebo group [85]. Using two well-
characterized strains (Lactobacillus rhamnosus GR-1
Fig. 2 Heatmap showing the distribution of bacterial taxa found in the vaginal microbial communities of 394 reproductive-age women in the
U.S. Adapted with permission from Proceedings of the National Academy of Sciences of the United States of America [70]
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and Lactobacillus fermentum RC-14), delivered by oral
capsules, Reid et al. [86] reported a significant in-
crease in vaginal lactobacilli on Gram stain and cul-
ture at day 28 and 60 in a randomized, placebo-
controlled trial of 64 healthy women. Martinez et al.
combined antibiotics and probiotics in a study of 32
women randomized to oral capsules of Lactobacillus
rhamnosus GR-1 and Lactobacillus reuteri RC-14 fol-
lowing 2 g of tinidazole, and reported a BV cure rate
at four weeks of 87 % in the Lactobacillus group
compared to 50 % in the tinidazole-only group [87].
Although recent results are encouraging, these are rela-
tively small studies with varying exclusion criteria and
short follow-up. The overall conclusions of the recent
Cochrane review and the latest U.S. CDC treatment
guidelines are that current evidence does not yet support
the addition of any available Lactobacillus formulations or
probiotics as an adjunctive or replacement therapy in
women with BV [80, 88]. There clearly remains a need
for larger, well-designed, double-blind, placebo-
controlled trials of various probiotic formulations, in
combination with, or in comparison to, standard
treatments. Probiotic trials need to standardize their
methods for evaluating BV and given the high recur-
rence rates reported in trials that extend follow up
to 6–12 months [40, 42], studies with more pro-
longed of observation post-treatment are important.
As some evidence suggests a woman’s endogenous
microbiota may impact on probiotic success rates, it
is likely that future therapeutic approaches will need
Fig. 3 Daily temporal dynamics of vaginal bacterial communities in six women over a 10-week period. The relative abundance of each bacterial taxa is
depicted as interpolated bar graphs. The bacterial taxa are indicated on the right of each bar graph with color codes. Daily Nugent Gram stain scores
(range 0–10) and pH (range 4–7) are indicated below the graph. Red solid circles represent menstruation. Missing pH values are indicated by red box,
otherwise pH is in line with a value of 4. Missing Nugent scores are also indicated by the red box, otherwise the score is in line with 0. The figure illustrates
that the top four participants (a, b, c, d) carry highly stable communities dominated by L. crispatus (a), L. iners (b) and non-Lactobacillus dominated
communities (c and d). Women e and f experienced unstable communities with both high Nugent scores and pH. Adapted with permission from
Microbiome [78]
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to include personalized probiotic or prebiotic recom-
mendations based on a woman’s individualized tem-
poral CST pattern.
Another adjunctive approach that is being investigated
to try and reduce BV following antibiotic therapy is hor-
monal contraception (HC). Epidemiological data, includ-
ing a meta- analysis, suggest that oral contraceptive pills
(OCP) are associated with a decreased risk of prevalent
and incident BV, Figs. 4 and 5 [51, 89–93]. This meta-
analysis also suggested that progestin-only oral contra-
ceptives (POC) reduce BV to a similar magnitude seen
with combined hormonal contraceptives [93]. Data on
the influence of contraceptive vaginal rings on the
local microenvironment are still sparse [94, 95], and
there is inconsistent evidence on how copper and
hormonal intrauterine devices (IUD) affect the vaginal
microbiome [90, 96–98]. Overall, where data on HC
are conflicting, it is most likely due to a number of
Fig. 4 Meta-analysis of hormonal contraception and prevalent BV. Figure first published in PLoS One [93]
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factors including the heterogeneity of approaches used
to diagnose BV, the formulation, regimen compliance
and duration of HC use, and the observational nature
of the studies. Sexual behaviours, and particularly
condom usage, may also confound the relationship
between contraceptive method and BV [97].
The effect of HC on BV and the vaginal microbiota is
likely mediated by sex hormones and their effects on
the genital microenvironment and immune response.
Adequate estrogen levels increase glycogen production
in vaginal epithelial cells, and glycogen is broken down
by human alpha-amylase into metabolites used by
Lactobacillus spp. to thrive and produce lactic acid [99].
HC, especially those containing progestins, also inhibit
uterine bleeding and reduce menstrual loss. Menstru-
ation has been strongly correlated with abnormal vagi-
nal microbiota [77, 79, 100], perhaps due to blood being
a more favourable environment for growth of iron-
requiring BV-associated bacteria. HC may also promote
a favourable anti-inflammatory cytokine milieu that fa-
cilitates BV clearance, either independently or mediated
by the microbiota.
Despite >50 years of widespread use, the effect of HC
on mucosal responses and the vaginal microbiota are
still incompletely understood. Few studies have fully
assessed changes in the vaginal microbiome after initi-
ation or cessation of HC. For a more thorough examin-
ation of the complex relationship between HC and the
vaginal microenvironment, we refer the readers to a re-
view by Achilles et al. [101] and meta-analysis by
Vodstricil et al. [93]. Future work will clarify whether
use of specific HCs are definitively associated with a re-
duced risk of BV. Investigators are also evaluating lactic
acid in the form of a vaginal gel and vaginal ring to de-
termine if it prevents BV, which may be a future thera-
peutic option alone or in combination with HCs.
New strategies to disrupt BV-associated vaginal biofilm
As increasing evidence has emerged that BV may be a
biofilm-associated disease, an interest has emerged in
agents that are primarily aimed at disrupting BV-
associated biofilm [102]. It may be necessary to break-
down biofilm to achieve optimal efficacy of antimicrobial
or probiotic therapies. Potential candidates that have
been investigated include: vaginal boric acid, DNases,
retrocyclins, octenidine and some naturally occurring
antimicrobials (subtilosin, ploy-L-lysine, lauramide ar-
ginine ethyl ester) [103]. Boric acid and octenidine are
the only compounds that have been used in human
studies, while the remainder have been evaluated in in
vitro studies against a G.vaginalis-biofilm [104, 105].
Boric acid (H3BO3), a white, odorless powder, was first
used by Lister as a topical antiseptic in 1873 [106], and
has been used in the treatment of vulvovaginal candidia-
sis [107–112] and Trichomonas vaginalis [113]. Vaginal
boric acid has bacteriostatic and fungistatic action, yet
Fig. 5 Meta-analysis of hormonal contraception and incident BV. Figure first published in PLoS One [93]
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its mechanism of action is unknown [114]. Boric acid
may work on BV through decimation of the vaginal
biofilm or change in the acidity of the vagina, while
the fungistatic activity may be attributed to fungal
cell wall penetration or disruption of the fungal cell
membrane [115]. Intravaginal boric acid has a long his-
tory of clinical use in the treatment of vaginitis and is
regarded as a safe secondary regimen [104, 111]. Blood
boron analyses indicates little absorption from the
vagina [116], and boric acid does not appear to cause
adverse changes on cervical cytology [109]. Vulvovagi-
nal burning, watery discharge, erythema, as well as male
dyspareunia, are the most frequently reported adverse
events reported by a minority of women [109, 115, 117].
Reichman et al. reported on a study of 7 days of oral
nitroimidazole administered to 58 women with recur-
rent BV. Imidazole therapy was followed by 21 days of
intravaginal boric acid (600 mg/day) and 16 weeks of
suppressive metronidazole gel maintenance therapy if in
remission at 21 days [104]. Patients reported symptom
improvement and a high cure rate (87 %) at 2–3 months
on treatment, however, by 38 weeks off treatment the
BV recurrence rate was 50 %. Current ongoing research
is examining how boric acid-based treatments, en-
hanced with an EDTA excipient to boost antimicrobial
activity, may be active against the vaginal biofilm and be
a potential candidate for BV treatment [118].
Swidsinski recently reported on the use of the topical
antiseptic, octenidine dihydrochloride, for BV-associated
biofilm [119]. Octenidine has broad spectrum antimicro-
bial activity and has been found to be highly effective
against biofilms in oral, wound and orthopaedic implant
infections [120–123]. Twenty-four patients with recur-
rent BV were treated with a 7 day intravaginal course of
octenidine dihydrochloride spray, and if they failed treat-
ment or recurred within 6 months, they were retreated
with a 28 day regimen followed by weekly applications
for 2 months [119]. Biofilm was evaluated by fluores-
cence in situ hybridization on voided vaginal epithelial
cells. While early cure rates looked promising after 7 days
of topical octenidine (87.5 %), six month recurrence
rates were high (66.6 %). Repeated treatment for 28 days
led to an overall cure rate of 75 %, however, complete
bacterial resistance to octenidine occurred in a subset of
women. Overall, while initial cure rates looked promis-
ing, the efficacy of prolonged and repeated treatment
was poor and bacterial resistance emerged in a signifi-
cant proportion of women.
Another novel strategy involves the use of DNAse which
targets extracellular DNA (eDNA) [105]. G. vaginalis bio-
films contain eDNA which is integral to their structural in-
tegrity. Enzymatic disruption of eDNA specifically inhibits
biofilm formation and established biofilms. In vitro studies
show that low concentrations of DNase and metronidazole
have improved efficacy against G. vaginalis biofilm com-
pared with either agent alone, presumably because DNase
frees G. vaginalis from the biofilm and renders bacteria
more susceptible to the antibiotic. Other in vitro studies
have included evaluation of an anti-HIV microbicide
candidate RC-101, a synthetic retrocyclin, which is an
antimicrobial peptide with antiviral activity. RC-101 has
been shown to potently inhibit the activity of vaginoly-
sin, a protein toxin produced by G. vaginalis, and the
formation of G. vaginalis biofilms in vitro, without af-
fecting Lactobacillus spp. [124, 125]. Vaginolysin inhib-
ition has been proposed as a potential strategy for BV
treatment and prevention [124, 125]. While RC 101
inhibited the formation of GV biofilms, it is not clear if
the mechanism is predominantly mediated through
vaginolysin inhibition, or another substance involved in
biofilm assembly [124, 125]. RC101 may be a candidate
for human BV studies. Lastly, a novel area of research
involves investigation of agents that inhibit quorum
sensing. Quorum sensing is used by some bacterial spe-
cies such as Pseudomonas aeruginosa and Staphylococ-
cus epidermidis to co-ordinate expression of genes
involved in virulence, biofilm formation and pathogen-
icity [126]. Quorum sensing inhibitors have not yet been
evaluated in human studies or BV, but have been shown
to be active in vitro against biofilms produced by Pseudo-
monas aeruginosa and Staphylococcus spp. [126, 127].
Clearly the identification of novel therapeutics that could
be used safely in human trials alone or as adjunctive ther-
apies to antibiotics for biofilm-inhibition and disruption is
an emerging area of research. For a thorough review of
the potential contribution of biofilm to treatment failure
and recurrence in BV, we refer readers to an excellent re-
cent publication by Muzny and Schwebke [102].
Conclusion
No major therapeutic advances have been made in over
20 years that have achieved significant improvements in
BV cure rates. We have only begun to understand the
importance of the vaginal microbiome and how changes
in its composition and function can affect women’s
health. Approaches that aim to restore a woman’s
“healthy” vaginal microbiome and maintain homeostasis
are much needed to prevent recurrent BV and its seque-
lae, including transmission and acquisition of HIV and
adverse obstetric outcomes, such as preterm birth.
While it is fundamentally unknown if BV recurrence is
principally due to persistence of BVAB and biofilm, a
failure to re-establish a favourable Lactobacillus-domin-
ant vaginal microbiota, reinfection or a combination of
these factors, it is challenging to make progress. While
evaluating many current and proposed therapies it is
important to consider the possibility that reinfection
from partners may also be impacting on our ability to
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determine the efficacy of these agents. Clinicians and
researchers in the field consider it an urgent priority
to develop new and innovative approaches to the manage-
ment of BV in order to achieve high and sustained long-
term cure rates, to develop effective prevention strategies
and to reduce BV-associated sequelae. In order to achieve
sustained cure it is possible, even likely, that we may need
an approach that combines a number of these strategies
such as use of antibiotics with biofilm-disrupting agents
and partner treatment.
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